Glioblastoma multiforme studied with analytical chemistry

Analytical chemistry has been used to study glioblastoma multiforme (GBM).

Published in Proteome Science, the researchers highlight that GBM's genomics, proteomics and transcriptomics could act as biomarkers for therapies, which could include immunotherapy.

Electrophoretic separations and mass spectrometry were used in the study in order to "identify proteins that may serve as brain tumour antigens".

Five samples were compared with Difference In-gel Analysis Software, the researchers explain - and using mass spectrometry 22 proteins were identified.

"Our results confirmed the importance of previously described proteins in glioma pathology and their potential usefulness as biological markers but also revealed some new interesting targets for future therapies," comment the scientists.

Proteome Science is an online journal that publishes papers on proteomics - both structural and functional.

The research released on the site is reviewed by peers prior to being published in an open-access format as soon as possible after approval.